335 related articles for article (PubMed ID: 12688834)
1. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis.
Etminan M; Gill S; Samii A
Drug Saf; 2003; 26(6):439-44. PubMed ID: 12688834
[TBL] [Abstract][Full Text] [Related]
2. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials.
Etminan M; Samii A; Takkouche B; Rochon PA
Drug Saf; 2001; 24(11):863-8. PubMed ID: 11665873
[TBL] [Abstract][Full Text] [Related]
3. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.
Kulisevsky J; Pagonabarraga J
Drug Saf; 2010 Feb; 33(2):147-61. PubMed ID: 20082541
[TBL] [Abstract][Full Text] [Related]
4. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
Inzelberg R; Schechtman E; Nisipeanu P
Drugs Aging; 2003; 20(11):847-55. PubMed ID: 12964891
[TBL] [Abstract][Full Text] [Related]
5. New pharmacotherapy for Parkinson's disease.
Gottwald MD; Bainbridge JL; Dowling GA; Aminoff MJ; Alldredge BK
Ann Pharmacother; 1997 Oct; 31(10):1205-17. PubMed ID: 9337447
[TBL] [Abstract][Full Text] [Related]
6. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
Dooley M; Markham A
Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
[TBL] [Abstract][Full Text] [Related]
7. Ropinirole for levodopa-induced complications in Parkinson's disease.
Clarke CE; Deane KH
Cochrane Database Syst Rev; 2001; (1):CD001516. PubMed ID: 11279718
[TBL] [Abstract][Full Text] [Related]
8. Ropinirole for levodopa-induced complications in Parkinson's disease.
Clarke CE; Deane KH
Cochrane Database Syst Rev; 2000; (3):CD001516. PubMed ID: 10908503
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome.
Quilici S; Abrams KR; Nicolas A; Martin M; Petit C; Lleu PL; Finnern HW
Sleep Med; 2008 Oct; 9(7):715-26. PubMed ID: 18226947
[TBL] [Abstract][Full Text] [Related]
10. Indirect Comparison of Ropinirole and Pramipexole as Levodopa Adjunctive Therapy in Advanced Parkinson's Disease: A Systematic Review and Network Meta-Analysis.
Zhao H; Ning Y; Cooper J; Refoios Camejo R; Ni X; Yi B; Parks D
Adv Ther; 2019 Jun; 36(6):1252-1265. PubMed ID: 30963514
[TBL] [Abstract][Full Text] [Related]
11. Pramipexole for levodopa-induced complications in Parkinson's disease.
Clarke C E; Speller J M; Clarke J A
Cochrane Database Syst Rev; 2000; 2000(3):CD002261. PubMed ID: 10908540
[TBL] [Abstract][Full Text] [Related]
12. Pramipexole, ropinirole, and mania in Parkinson's disease.
Singh A; Althoff R; Martineau RJ; Jacobson J
Am J Psychiatry; 2005 Apr; 162(4):814-5. PubMed ID: 15800169
[No Abstract] [Full Text] [Related]
13. Ropinirole and pramipexole, the new agonists.
Hobson DE; Pourcher E; Martin WR
Can J Neurol Sci; 1999 Aug; 26 Suppl 2():S27-33. PubMed ID: 10451757
[TBL] [Abstract][Full Text] [Related]
14. Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Clarke C E; Speller J M; Clarke J A
Cochrane Database Syst Rev; 2000; 2000(3):CD002259. PubMed ID: 10908539
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the Efficacy of Different Drugs on Non-Motor Symptoms of Parkinson's Disease: a Network Meta-Analysis.
Li BD; Cui JJ; Song J; Qi C; Ma PF; Wang YR; Bai J
Cell Physiol Biochem; 2018; 45(1):119-130. PubMed ID: 29339630
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease.
Wong KS; Lu CS; Shan DE; Yang CC; Tsoi TH; Mok V
J Neurol Sci; 2003 Dec; 216(1):81-7. PubMed ID: 14607306
[TBL] [Abstract][Full Text] [Related]
17. Dopamine agonist monotherapy in Parkinson's disease.
Clarke CE; Guttman M
Lancet; 2002 Nov; 360(9347):1767-9. PubMed ID: 12480442
[TBL] [Abstract][Full Text] [Related]
18. An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease.
Lyons KE; Pahwa R
Mov Disord; 2009 Oct; 24(14):2121-7. PubMed ID: 19768728
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of the efficacy and safety of long-acting non-ergot dopamine agonists in Parkinson's disease.
Zhou CQ; Zhang JW; Wang M; Peng GG
J Clin Neurosci; 2014 Jul; 21(7):1094-101. PubMed ID: 24786715
[TBL] [Abstract][Full Text] [Related]
20. Pramipexole and ropinirole for Parkinson's disease.
Med Lett Drugs Ther; 1997 Nov; 39(1014):109-10. PubMed ID: 9398824
[No Abstract] [Full Text] [Related]
[Next] [New Search]
